Irwig M S, Childs K, Hancock A B
Division of Endocrinology and Center for Andrology, The George Washington University, Washington, DC, USA.
Department of Speech and Hearing Sciences, The George Washington University, Washington, DC, USA.
Andrology. 2017 Jan;5(1):107-112. doi: 10.1111/andr.12278. Epub 2016 Sep 19.
There is sparse prospective data on the effects of testosterone therapy on the voices of transgender men (also referred to as trans men or female-to-male transsexuals). Our aim was to investigate the timing and degree of voice deepening over 12 months among an ethnically diverse sample of transgender men. This was a prospective 12-month study at an academic outpatient endocrinology clinic and speech and voice center. The participants were seven transgender men naïve to testosterone therapy. All patients received two voice assessments at baseline and one assessment at 3, 6, 9, and 12 months while on intramuscular testosterone esters. Serum testosterone and estradiol concentrations were measured at baseline and every 3 months. All seven transgender men reached a cisgender male mean fundamental frequency (MF0) within 6 months of testosterone therapy and four continued to experience a decrease after 6 months. The mean decrease in MF0 after 12 months of testosterone therapy was 6.4 semitones (49 Hz). Several patterns emerged regarding the extent and timing. For example, some participants showed no decrease in MF0 within the first 3 months of testosterone therapy, whereas others showed their greatest decrease in MF0. We concluded that transgender men who start testosterone therapy display different patterns of voice lowering. Clinicians should counsel transgender men that they may or may not experience voice lowering within the first 3 months of testosterone therapy and that the majority of voice deepening will occur within 6-9 months.
关于睾酮疗法对跨性别男性（也称为变性男性或女变男的变性者）声音的影响，前瞻性数据较少。我们的目的是在一个种族多样化的跨性别男性样本中，调查12个月内声音变低沉的时间和程度。这是在一家学术门诊内分泌诊所和语音中心进行的为期12个月的前瞻性研究。参与者是7名未接受过睾酮疗法的跨性别男性。所有患者在基线时接受两次声音评估，并在接受肌肉注射睾酮酯治疗期间的3、6、9和12个月各接受一次评估。在基线时以及每3个月测量血清睾酮和雌二醇浓度。所有7名跨性别男性在接受睾酮疗法的6个月内达到了顺性别男性的平均基频（MF0），其中4人在6个月后MF0继续下降。睾酮疗法12个月后MF0的平均下降幅度为6.4个半音（49赫兹）。出现了几种关于下降程度和时间的模式。例如，一些参与者在睾酮疗法的前3个月内MF0没有下降，而另一些参与者的MF0下降幅度最大。我们得出结论，开始接受睾酮疗法的跨性别男性表现出不同的声音降低模式。临床医生应告知跨性别男性，他们在睾酮疗法的前3个月内可能会或可能不会经历声音降低，并且大部分声音变低沉将在6至9个月内发生。
